| 1 |
35247515 | Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. | 2022 May 28 |
1 |
| 2 |
33190426 | Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm. | 2021 Mar |
3 |
| 3 |
34645844 | Disulfide-compatible phage-assisted continuous evolution in the periplasmic space. | 2021 Oct 13 |
1 |
| 4 |
31691197 | Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity. | 2020 Jan |
1 |
| 5 |
32010829 | Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates. | 2020 Jan 28 |
1 |
| 6 |
33210532 | DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages. | 2020 Dec 16 |
1 |
| 7 |
30718919 | A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. | 2019 May |
2 |
| 8 |
31460422 | Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. | 2019 Jul 31 |
1 |
| 9 |
31513391 | HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor. | 2019 Oct 14 |
1 |
| 10 |
31726009 | Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate. | 2019 Dec 18 |
3 |
| 11 |
29348271 | Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. | 2018 Mar |
1 |
| 12 |
30040421 | Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates. | 2018 Sep 4 |
1 |
| 13 |
28423644 | Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. | 2017 Apr 25 |
3 |
| 14 |
26254483 | Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis. | 2016 Jan |
1 |
| 15 |
25635711 | Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. | 2015 Jun 1 |
1 |
| 16 |
25865227 | Novel agents that downregulate EGFR, HER2, and HER3 in parallel. | 2015 Apr 30 |
1 |
| 17 |
25121341 | Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery. | 2014 Sep 17 |
2 |
| 18 |
22272277 | Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. | 2012 |
1 |
| 19 |
22908275 | Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | 2012 Sep 4 |
1 |
| 20 |
21428412 | Characterization and comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: using LC-MS with electron transfer dissociation. | 2011 Apr 15 |
1 |
| 21 |
19589785 | HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. | 2009 Sep 11 |
1 |
| 22 |
17513761 | Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. | 2007 Jun 1 |
2 |
| 23 |
15507452 | Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. | 2005 Jan 7 |
2 |
| 24 |
11796015 | Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. | 2002 Feb |
2 |
| 25 |
9637257 | An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. | 1998 May 15 |
1 |
| 26 |
9710621 | Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. | 1998 Sep |
2 |
| 27 |
9346940 | Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. | 1997 Oct 31 |
1 |
| 28 |
8608123 | Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. | 1996 Mar 5 |
1 |
| 29 |
8840431 | Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. | 1996 |
1 |
| 30 |
7805042 | Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. | 1995 Jan 1 |
1 |
| 31 |
7913461 | Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. | 1994 Jul 15 |
1 |
| 32 |
1379605 | Disulfide-linked and noncovalent dimers of p185HER-2 in human breast carcinoma cells. | 1992 Jul |
1 |